The prevalence of metabolic diseases such as fatty liver, dyslipidemias, diabetes and hypertension, has become a healthcare crisis in many countries. The incidence has dramatically increased despite large expenditure in prevention. Just for diabetes, the average annual incidence in the last 20 years has been 12.5 million. It is estimated that the worldwide prevalence is more than 415 million (King, Aubert, and Herman 1998; Ogurtsova et al. 2017). The incidence of diabetes is also increasing among age groups usually considered free from chronic diseases, such as children and adolescents (Mayer-Davis et al. 2017).
Since there is no know cure for these metabolic diseases, the best practices can only aim to “manage” the disease. Can we improve the management of the disease?
The Tepoztlan Lifestyle intervention program aimed to offer a more efficient, easier to implement alternative to the current metabolic.
You can download related documents of the intervention here.
Since there is no know cure for these metabolic diseases, the best practices can only aim to “manage” the disease. Can we improve the management of the disease?
The Tepoztlan Lifestyle intervention program aimed to offer a more efficient, easier to implement alternative to the current metabolic.
You can download related documents of the intervention here.
|
| ||||
